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Introduction: The present study compares the clinical, pathological and molecular features of a United States (US)
case of growth hormone (GH)-associated Creutzfeldt-Jakob disease (GH-CJD) (index case) to those of two earlier
referred US cases of GH-CJD and one case of dura mater (d)-associated CJD (dCJD). All iatrogenic CJD (iCJD) subjects
were methionine (M) homozygous at codon 129 (129MM) of the prion protein (PrP) gene and had scrapie prion
protein (PrPSc) type 1 (iCJDMM1).
Results: The index subject presented with ataxia, weight loss and changes in the sleep pattern about 38 years
after the midpoint of GH treatment. Autopsy examination revealed a neuropathological phenotype reminiscent
of both sCJDMV2-K (a sporadic CJD subtype in subjects methionine/valine heterozygous at codon 129 with PrPSc
type 2 and the presence of kuru plaques) and variant CJD (vCJD). The two earlier cases of GH-CJDMM1 and the
one of dCJDMM1 were associated with neuropathological phenotypes that differed from that of the index case
mainly because they lacked PrP plaques. The phenotype of the earlier GH-CJDMM1 cases shared several, but not all,
characteristics with sCJDMM1, whereas dCJDMM1 was phenotypically indistinguishable from sCJDMM1. Two distinct
groups of dCJDMM1 have also been described in Japan based on clinical features, the presence or absence of PrP
plaques and distinct PK-resistant PrPSc (resPrPSc) electrophoretic mobilities. The resPrPSc electrophoretic mobility was,
however, identical in our GH-CJDMM1 and dCJDMM1 cases, and matched that of sCJDMM1.
Conclusions: Our study shows that receipt of prion-contaminated GH can lead to a prion disease with molecular
features (129MM and PrPSc type 2) and phenotypic characteristics that differ from those of sporadic prion disease
(sCJDMM1), a difference that may reflect adaptation of “heterologous” prion strains to the 129MM background.
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The first case of iatrogenic Creutzfeldt-Jakob disease
(iCJD) was described in 1974, in a recipient of corneal
graft from a donor who died following a rapidly progres-
sive dementing illness [1]. Subsequently, other mechanisms
of iatrogenic transmission were identified worldwide.
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human primates [2–5]. More than 230 cases, mostly in
France, of iCJD have been linked to injection of prod-
ucts extracted from cadaveric pituitary glands, including
growth hormone (GH) (at least 226 cases) and gonado-
tropin (4 cases). Worldwide, a similar number of iCJD
cases (at least 228 cases) have been associated with re-
ceipt of dura mater grafts, especially in Japan where
greater than 60 % of all dura mater (d)-associated CJD
(dCJD) cases have been identified [6, 7]. More recently,
blood products from subjects who were later diagnosed
with variant CJD (vCJD) have also been reported to
transmit vCJD, resulting in iCJD cases [8–10]. Unliketributed under the terms of the Creative Commons Attribution License (http://
permits unrestricted use, distribution, and reproduction in any medium, provided
ative Commons Public Domain Dedication waiver (http://creativecommons.org/
ade available in this article, unless otherwise stated.
Cali et al. Acta Neuropathologica Communications  (2015) 3:37 Page 2 of 10the vast majority of vCJD cases, the mechanism of which
is based on exogenous scrapie prion protein (PrPSc) cross-
ing the species barrier, iCJD is entirely a human disease
which is transmitted from person to person.
The detailed pathology of GH-associated CJD (GH-CJD)
with methionine (M) homozygous genotype at codon 129
(129MM) of the prion protein (PrP) gene has been reported
in 1993–1994 in three French cases who had brain kuru
plaques and detectable proteinase K (PK)-resistant PrPSc
(resPrPSc) [11] or positive PrP immunostaining [12]. Infor-
mation on the type of resPrPSc (e.g., type 1 and type 2),
however, was not available until 1994 [13]. More recently,
a GH-CJDMM case with resPrPSc type 1 (GH-CJDMM1)
was reported to show the diffuse or “synaptic” PrP immu-
nostaining and no PrP plaques [14].
We have studied the clinical, pathological and molecu-
lar features of a United States (US) GH-CJD case that
died in 2013 (index case) and compared the features of
the index case to those of two earlier cases of GH-CJD
and one dCJD case [15] referred to the US National
Prion Disease Pathology Surveillance Center (NPDPSC)
(Table 1). All four patients shared codon 129MM geno-
type and resPrPSc type 1. From this comparative study,
two pathological phenotypes were observed in GH-
CJDMM1; the first phenotype was characterized by dif-
ferent types of PrP aggregates, including kuru plaques,
and some histopathological features of vCJD, such as
florid plaques and “stellate” cells highlighted by the peri-
cellular deposition of PrP [16]. This phenotype therefore
shared features of both sCJDMV2-K and vCJD and was
observed in our index case [17–19]. The second pheno-
type, observed in the two other GH-CJDMM1 cases,
was characterized by the absence of PrP plaques and had
several, but not all, characteristics of sCJDMM1. Finally,
the dCJDMM1 case showed a phenotype indistinguish-
able from that of sCJDMM1 (Table 1).
Two different phenotypes have also been described in
Japanese cases of dCJD, which were referred to, depend-
ing on the presence or absence of PrP plaques, as
“plaque-type dCJD” (p-dCJD) or “non-plaque-type
dCJD” (np-dCJD). Both groups shared the same codon
129MM genotype (one np-dCJD and one p-dCJD were
129MV) although the unglycosylated resPrPSc isoform
in p-dCJD had about 1 kDa faster mobility than unglycosy-
lated resPrPSc from np-dCJD and sCJDMM1 (e.g., ~20 kDa
vs. ~21 kDa, respectively) [20]. The NPDPSC dCJDMM1
case had pathological and molecular features (electrophor-
etic mobility of resPrPSc) that were indistinguishable from
those of sCJDMM1, similar to the np-dCJD cases.
Materials and methods
Reagents and antibodies
Dulbecco’s Phosphate Buffered Saline (DPBS), Phenyl-
methanesulfonyl fluoride (PMSF) and Proteinase Kwere from Sigma-Aldrich (St. Louis, MO, USA). Tween
20, 10X Tris/glycine, 10X Tris/Glycine/SDS, 2X Laemmli
Sample Buffer, β –mercaptoethanol and Criterion
15 % Tris–HCl polyacrylamide precast gels were from
Bio-Rad Laboratories (Hercules, CA, USA). Odyssey
blocking buffer, Infrared Dye (IRDye) 800CW goat
anti-mouse IgG (1 mg/ml), IRDye 680RD goat anti-
rabbit IgG (1 mg/ml) and the Polyvinylidene difluoride
(PVDF) membrane (Immobilon-FL) were from LI-
COR Biosciences (Lincoln, NE, USA). The 3F4 mono-
clonal antibody to PrP residues 106–110 [21, 22],
12B2 monoclonal antibody to PrP residues 89–93 (this
epitope is not preserved in resPrPSc type 2) [23], and
the polyclonal antibody Tohoku-2 to PrP residues 97–103
[24] were used in this study.
Tissue samples and subject selection
At brain autopsies, one half was frozen and stored at
−80 °C and the other half was fixed in formalin for
neuropathological examination. Brain tissue was sent
to the NPDPSC for analysis. Frozen brain tissue used
for the molecular study was from the frontal cortex
[GH-CJDMM1 (N = 3), dCJDMM1 (N = 1), sCJDMM1
(N = 3), sCJDMV2-K (N = 3)] and cerebellum [GH-
CJDMM1 (N= 2), dCJDMM1 (N= 1), sCJDMM1 (N = 3),
sCJDMV2-K (N = 3)]. Subjects were diagnosed as
sCJDMM1 and sCJDMV2-K according to Parchi et al.
[19, 25]. Mean ages at disease onset and disease dura-
tions were 70 ± 15 (standard deviation, SD) years and
2 ± 0.1 (SD) months in sCJDMM1, and 64 ± 9 (SD)
years and 10 ± 3 (SD) months in sCJDMV2-K, re-
spectively. These two sCJD subtypes (sCJDMM1 and
sCJDMV2-K) were chosen as control cases for two
reasons: (1) all iatrogenic CJD (iCJD) cases in this
study shared with sCJDMM1 the 129 genotype and
resPrPSc type 1; (2) one of the three iCJD cases (the
index case, case 1 of Table 1) shared some histological
and immunohistochemical features with sCJDMV2-K.
In addition to case 1, the GH-CJDMM1 (cases 2 and
3, Table 1) and dCJD subjects (case 4, Table 1) [15]
reviewed at the NPDPSC had age at disease onset of
54, 40 and 39 years, disease duration of 2, 2 and
3 months and incubation period (from mid-point of
GH-therapy or receipt of the dural graft) of 41.5, 26.3
and 6 years, respectively. All patient protocols were
approved by the Institutional Review Boards of the Uni-
versity Hospitals Case Medical Center.
Preparation of brain tissues and proteinase K digestion
A 20 % (wt/vol) brain homogenate (BH) in 1X Dulbecco’s
PBS (DPBS) was mixed 1:1 with the 2X LB100 buffer (1X
LB100: 100 mM NaCl, 0.5 % Nonidet P-40, 0.5 % sodium
deoxycholate, 10 mM EDTA, 100 mM Tris–HCl, pH 8.0)
[26, 27]. The resulting 10 % BH was centrifuged at 1000 g
Table 1 Clinical, molecular and pathological features of the iatrogenic CJD patients of this study and sporadic CJDMM1
Prion disease GH-CJDMM1 GH-CJDMM1 GH-CJDMM1 dCJDMM1 sCJDMM1 (203 cases)a
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a[19, 46]; bmean; crange; considered from the dthe midpoint of treatment with GH or ethe time of grafting surgery to the appearance of the first clinical
sign/symptoms; fSD: spongiform degeneration; gSN: substantia nigra; hIHC: immunohistochemistry; (−) absent, (+) mild, (++) moderate, (+++) severe
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S1 was incubated with proteinase K (PK) at 37 °C for
1 hour. The PK concentration used was equal to 10 U/ml
[48 U/mg specific activity at 37 °C, with 1 U/ml equal to
20.8 mg/ml PK]. The enzymatic reaction was stopped with
3 mM PMSF. Each sample was mixed 1:1 with the 2X
Laemmli sample buffer (6 % SDS, 20 % glycerol, 4 mMEDTA, 5 % β –mercaptoethanol, 125 mM Tris–HCl,
pH 6.8) and denatured for 10 minutes at 100 °C.
Western blot analysis
Proteins were loaded onto a 15 % Criterion Tris–HCl
polyacrylamide precast gel for gel electrophoresis, blotted
into the Immobilon-FL PVDF membranes for 2 hours,
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nutes and incubated with the 3F4 (1:20,000), 12B2
(0.1 μg/ml) or Tohoku 2 (1:20,000) for 2 hours. Mem-
branes were washed with DPBS-T (1X DPBS with
0.1 % Tween 20) and incubated with IRDye 800CW
goat anti-mouse IgG (1:15,000) or IRDye 680RD goat
anti-rabbit IgG (1:15,000) for 1 hour. After washing
with DPBS-T, membranes were developed by Odyssey
infrared imaging system (LI-COR Biosciences).
Histology and PrP immunohistochemistry
Histopathology and PrP immunohistochemistry were
performed as previously described [28]. Briefly, deparaf-
finized and rehydrated sections were immersed in Tris-
buffered saline-Tween 20 (TBS-T) and endogenous per-
oxidase blocked by Envision Flex Peroxidase Blocking
Reagent (Dako) for 10 minutes. Sections were washed,
immersed in 1.5 mmol/L hydrochloric acid, microwaved
for 15 minutes and incubated with 3F4 (1:1000) for
1 hour. After washing and incubation with Envision
Flex/HRP polymer for 30 minutes (Dako), sections were
treated with Envision Flex DAB (Dako) to show the
immunostaining.
Genetic analysis
DNA was extracted from frozen brain tissues and PrP
gene analysis performed as previously described [18, 29].
Results
Clinical history of the index case
A 50-year-old athletic male presented to his primary
physician with 18 months of erectile dysfunction, three
months of chronic dry cough, two months of right toe
numbness, unintentional 14 pounds weight loss over the
prior eight months, and one month (“onset”) of leg fa-
tigue and instability, disequilibrium (“like on a boat”),
and insomnia (early awakening). Running and jumping
had become difficult, and he had fallen during sports.
Physical examination reportedly was normal. Past med-
ical history was notable for idiopathic isolated growth
hormone deficiency treated with human growth hor-
mone from 6.5 to 18 years of age (received pituitary-
derived human growth hormone from the US National
Hormone and Pituitary Program between 1969 and
1980). At six weeks after motor onset he developed fre-
quent hot flashes, with whole-body sweating. At three
and a half months, at his first neurology consultation, he
could no longer run and had trouble using stairs due to
imbalance, was having intermittent episodes of horizon-
tal eye jerking with downgaze lasting seconds, intermit-
tent difficulty concentrating and remembering new
names, mild intermittent dysphagia, and a few episodes
of leg jerking mostly with startle, but his weight loss had
stabilized. His detailed neurological exam was normalexcept for finding tandem gait uncharacteristically chal-
lenging, moderate sway on Romberg, and decreased cold
perception below the ankles. By 5 months, he had wors-
ening of gait instability, insomnia, myoclonus/startle,
and numbness/tingling (spread to bilateral toes and
soles), and he noted muscle spasms/cramps as well as
exercise-induced body tremulousness. Exam showed
slight head tremor with visual pursuit, mild arm parato-
nia, spastic/ataxic gait, inability to tandem, positive
Romberg. By 6 months, he developed constipation, urin-
ary retention, worsening of “bouncing eyes,” intermittent
head jerking back, and exam showed new pendular nys-
tagmus with vertical gaze, asymmetric upper extremity
postural and intention tremor, brisk patellar reflexes, ab-
sent Achilles reflexes, diminished distal vibration and
pin prick perception, and slight orthostasis by pulse. By
7 months, he required catheterization for neurogenic
bladder. Paresthesias had ascended to the sacral level. By
9 months, he was anxious with pressured speech, walker
dependent with orthostatic lower extremity tremor and
appendicular ataxia. He was wheelchair bound by
10 months with hypophonia and intermittent focal and
generalized myoclonus. By 11 months, he had short term
memory loss, daytime hypersomnolence, polymyoclonus
and nightmares disrupting sleep, worsening dysphagia
and dysautonomia with anejaculation, and he had to
stop working primarily because of “bouncing eyes” af-
fecting vision. Extensive evaluation for autoimmune, in-
fectious, toxic, metabolic, neoplastic, paraneoplastic/
antibody-mediated, and genetic (spinocerebellar ataxias
1,2,3, and 6) causes of his symptoms was unremarkable
except for a transient elevation in venous lactate, mildly
elevated aldolase of 8.4 (normal < =8.1 unit/L), hemoglobin
A1c 5.9-6.0 (5.7-6.4 prediabetes range), high B-6 of
49.8 ng/mL (normal 2.1-21.7 ng/mL), low thiamine of 6
(normal 8–30 nmol/L), positive serum striational antibody
1:160, felt to be false-positive [30]. Cerebrospinal fluid
(CSF) at six months showed normal cells, protein, glucose,
high intermediate neuron-specific enolase of 30 ng/ml
(15–30 ng/ml intermediate, > 30 consistent with CJD,
Mayo Laboratories, Rochester, MN) and 14-3-3 negative
(<1.0 ng/mL, Mayo). CSF 14-3-3 was positive (Western
Blot) and total-tau elevated to 1517 pg/ml; (>1150 is con-
sistent with CJD per NPDPSC) at 11.5 months. Brain
magnetic resonance imaging (MRI) was normal at
4 months, progressed to restricted diffusion in the right
caudate head and more subtle cortical and possible super-
ior vermis involvement at 10 months, with progression to
bilateral asymmetric caudate and clear cerebellar vermis
involvement at 11.5 months (Fig. 1). Notably, the formal
reports missed the cerebellar and cortical involvement.
Electroencephalogram (EEG) at 11 months was normal
except for severe polymyoclonus causing arousals from
stage 2 sleep; at 11.5 months it showed occasional, very
Fig. 1 Brain MRIs of index case. a-e: MRI was normal at 4 months without clear evidence of restricted diffusion on DWI sequence (a), but
progressed to restricted diffusion in the right caudate head (solid arrows) and more subtle cortical (dashed arrows) and possible superior vermis
(dotted arrows) involvement at 10 months (b, DWI; c, ADC map), with progression to bilateral asymmetric caudate and more evident cerebellar
vermis involvement at 11.5 months (d, DWI; e, ADC map)
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wakefulness without periodic discharges. EMG/NCS at six
months showed a non length-dependent sensorimotor
polyneuropathy, and essentially unchanged at 8 months.
Vastus lateralis muscle biopsy (10 months) showed
minimal recent neurogenic muscle atrophy without
evidence of mitochondrial or other primary myopathy.
His cognitive impairment, daytime hypersomnolence,
myoclonus, subjective “eye jiggling,” anejaculation
worsened severely and he died 14 months after motor
onset. Brain-only autopsy was performed two days
post-mortem.Histopathology
Index case
Gliosis and spongiform degeneration (SD) affected the
gray matter of the entire brain although the basal gan-
glia, thalamus and midbrain showed more severe patho-
logical changes than the cerebral cortex where SD had a
laminar distribution affecting preferentially layers IV-VI
(Fig. 2a-d; case 1, Table 1). Furthermore, “ballooned”
neurons were occasionally observed in the cerebral cor-
tex (Fig. 2g). The cerebellum showed focal atrophy with
severe astrogliosis and loss of granule cells. Three types
of abnormal PrP aggregates were observed: i) kuru pla-
ques, occasionally in clusters, in the granular layer and,
less commonly, in the cerebral cortex and molecular
layer and deep white matter of the cerebellum; ii) kuru
plaques surrounded by vacuoles, resembling the florid
plaques of variant CJD (vCJD), in the cerebral cortex; iii)
eosinophilic plaque-like formations, often populated the
superficial cortical layers, were generally larger than, andlacked a dense core and the pale peripheral halo found
in, kuru plaques. (Fig. 2e-f, h).
Immunohistochemical examination revealed that the
PrP deposition was widespread throughout the brain; in
the cerebral cortex, it co-distributed with the laminar
SD and was either diffuse or distributed in plaque-like
and perineuronal patterns (Fig. 2i). The large and eosino-
philic plaque-like formations observed by hematoxylin
and eosin (HE) examination were intensely immunostained
(Fig. 2k). In the cerebellum, kuru plaques and plaque-like
formations also were very immunoreactive (Fig. 2j). Finally,
the cerebellar molecular layer as well as cortical and sub-
cortical brain regions showed an unusual pericellular PrP
deposition that highlighted cells apparently characterized
by a round perikaryon surrounded by short branching pro-
cesses (Fig. 2j-k, n-o). Similar cells have been observed in
variant CJD (vCJD) [16]. Occasionally, the cerebellar
“brush stroke-like” pattern of PrP deposition typical of the
sCJDMM1 subtype was also observed (Fig. 2m).The three earlier US iatrogenic CJD (iCJD) patients
The pathological examination of two GH-CJDMM1 pa-
tients (cases 2 and 3, Table 1) revealed fine SD affecting oc-
casionally the deeper layers of the cerebral cortex; the
hippocampus was spared in both cases whereas the ento-
rhinal cortex and anterior basal ganglia were virtually
spared and the occipital cortex had less severe SD than
frontal cortex in case 2. In the cerebellum, SD was focal in
case 2 and ubiquitous in case 3 (Fig. 3, rows i-ii and data
not shown). In dCJDMM1 (case 4, Table 1), a fine SD af-
fected homogeneously all layers of the cerebral cortex with
sparing of the hippocampus and focal distribution in the
Fig. 2 Histopathology and immunohistochemistry of the index US GH-CJD patient. a-h: Histopathology. a-c: Spongiform degeneration (SD)
selectively affecting the deeper layers of the cingulate gyrus (a; bracket), the hippocampal gyrus (b) and more severely the basal ganglia (c). c-d:
Reactive astrogliosis (circles) in basal ganglia (c) and midbrain substantia nigra (d); arrows in the inset (dashed square) indicate intraneuronal vacuole
formation. e: A kuru plaque in the frontal cortex reminiscent of the florid plaques observed in vCJD. f: A different type of plaque, apparently core-free,
was detected in the cortical (f, parietal cortex) and subcortical brain regions. (not shown) g: A ballooned neuron. h: Kuru plaques (arrows) in the cere-
bellar granular layer. i-q: Immunohistochemistry. i: Laminar PrP immunostaining of the insula. j: Kuru plaque (circles) and plaque-like (squares) PrP im-
munostaining in the cerebellar granular and molecular layers, and peri-cellular PrP (“stellate”) (arrow) in the molecular layer. k: Large PrP aggregates
(circle) and peri-cellular PrP immunostaining (“stellate” cells) (arrow) in proximity of one sulcus in the frontal cortex (dotted line delimiting the sulcus). i:
Intense PrP immunostaining of the hippocampus.m: “Brush stroke-like” PrP immunostaining in the molecular layer of the cerebellum. n-o: Higher magnifi-
cation of the PrP-immunostained “stellate” cells in the cerebellar molecular layer of the present case (n) and in one vCJD case (o). p-q: Intense PrP staining
of the dentate nucleus (p) and along processes around the perikaryon of a neuron of the frontal cortex (q). Scale bar of inset in d: 50 μm; antibody: 3F4
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rows i-ii). Immunohistochemical examination revealed the
presence synaptic PrP deposition in the brain, which
showed the “brush stroke-like” PrP pattern in the cerebellar
molecular layer of cases 2, 3 and 4 (Fig. 3, row iii).Fig. 3 Histopathology and immunohistochemistry of GH-CJDMM1 (cases 2
and PrP immunohistochemistry (row iii). i: No spongiform degeneration (SD
4 and sCJDMM1) and ubiquitous SD (case 3). Insets contain magnified regi
PrP immunostaining pattern (cases 2, 3, 4 and sCJDMM1). Scale bar of insets inPrPSc type determination
Index case
The electrophoretic profile of the PK-resistant PrPSc
(resPrPSc) from this GH-CJDMM1 patient was examined
in parallel with those of resPrPSc from sCJDMM1 (N= 3)and 3), dCJDMM1 (case 4) and sCJDMM1. Histopathology (rows i-ii)
) (case 2) and fine SD (cases 3, 4 and sCJDMM1). ii: Focal SD (cases 2,
ons delimited by rectangles in the main figure. iii: “Brush stroke-like”
ii: 100 μm; mol. L.: molecular layer; grl. L.: granular layer; antibody in iii: 3F4
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cases shared the molecular features (sCJDMM1) and some
aspects of the histopathological phenotype (sCJDMV2-K).
The unglycosylated resPrPSc isoform of GH-CJDMM1 co-
migrated at ~20 kDa with the unglycosylated resPrPSc type
1 associated with sCJDMM1. Probing with the antibodies
Tohoku-2 and 12B2 to PrPSc type 2 and type 1, respect-
ively, confirmed that the ~20 kDa contained exclusively
PrPSc type 1. In contrast, two bands populated by unglyco-
sylated resPrPSc fragments were observed in sCJDMV2-K:
a prominent ~19 kDa band that matched in electrophor-
etic mobility resPrPSc type 2, and a ~20 kDa thinner band
(Fig. 4a). Tohoku-2 confirmed the presence of resPrPSc
type 2 in the ~19 kDa band but not in the ~20 kDa
band of sCJDMV2-K. The ~20 kDa band has previ-
ously been described in subjects with the sCJDMV2-K
subtype [25, 31].
Other iCJD patients
The unglycosylated resPrPSc from GH-CJDMM1 (cases
2 and 3, Table 1) and dCJDMM1 (case 4, Table 1) co-
migrated at ~20 kDa with the unglycosylated resPrPSc
type 1 of sCJDMM1 as well as the ~20 kDa fragment of
sCJDMV2-K. The resPrPSc ~20 kDa fragments from all
iCJD cases immunoreacted with 12B2 but not with
Tohoku-2 antibody (Fig. 4b and data not shown).
Discussion
Our index case presented with dysautonomia, a dry
cough, neuropathy and cerebellar ataxia at age 50, ap-
proximately 38 years after growth hormone (GH)Fig. 4 Western blot of the PK-resistant PrPSc. Brain homogenates from the
GH-CJDMM1 (case 2), dCJDMM1 (case 4) and (a and b) control cases sCJDM
immunoblotting with antibodies (i) 3 F4, (ii) Tohoku-2, or (iii) 3 F4- and To
the index case co-migrated at ~20 kDa with the corresponding resPrPSc typ
The asterisk in i-iii indicates the unglycosylated resPrPSc type 2. ii: Only the
confirming that it belongs to type 2. Tohoku-2 immunoreacted also with a
in a by the filled and empty arrowheads, respectively) in the cerebellum of
rectangle in ii-(a) is shown below at a longer exposure time. iii: Merged 3midpoint of treatment, and died 14 months after
motor onset. Histopathological features were defined
by the presence of 1) homogeneous eosinophilic pla-
ques lacking a core, 2) typical kuru plaques occasion-
ally surrounded by vacuoles (florid plaques), and 3)
“stellate” cells highlighted by the pericellular depos-
ition of prion protein (PrP). Spongiform degeneration
(SD) with laminar distribution in the cerebral cortex
was associated with plaque, plaque-like and perineuro-
nal PrP immunostaining. PrP staining was also intense
in the hippocampus, subcortical brain regions and
dentate nucleus. Therefore, the neuropathological fea-
tures of this case mimicked those of sCJDMV2-K in
terms of the general topography and type of SD and
PrP immunoreactivity, as well as the presence of kuru
plaques. The neuropathological features differed from
those of sCJDMV2-K, however, by the presence of the
homogeneous “stellate” cells and occasionally florid
plaques in the cortical regions and “brush stroke-like”
staining in the cerebellum, the latter being a feature of
sCJDMM1. Furthermore, this patient was homozygous
for methionine at codon 129 (129MM) and showed the
PK-resistant PrPSc (resPrPSc) type 1, which in sCJD has
very different pathological features [19].
Two previous GH-CJDMM1 cases that were reviewed
at the NPDPSC presented at the age of 54 years with
“progressive weakness, ataxia and slurred speech” (case
2) and at the age of 40 years with “progressive body stiff-
ness and writhing that developed into left leg numbness
and broad based gait” (case 3), approximately 41.5 years
(case 2) and 26.3 years (case 3) after GH midpoint offrontal cortex (FC) and the cerebellum (CE) of (a) the index case, (b)
V2-K and sCJDMM1 were treated with 10 U/ml PK (~200 μg/ml) prior
hoku-2-merged immunoreactivities. i: The unglycosylated resPrPSc from
e 1 of sCJDMM1 and with a ~20 kDa fragment of sCJDMV2-K (arrow).
resPrPSc associated with sCJDMV2-K (asterisk) reacted with Tohoku-2
resPrPSc fragment of ~18.0 kDa and to a lower size fragment (indicated
sCJDMV2-K, but not with the resPrPSc ~20 kDa fragment. The dashed
F4 (green dye) and Tohoku-2 (red dye) immunoreactivities
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ease course. Pathologically, both showed a phenotype
reminiscent of sCJDMM1. Similar to sCJDMM1, both
cases i) lacked amyloid plaques, ii) showed fine SD and
“synaptic” PrP immunostaining that iii) spared the
hippocampus. Unlike sCJDMM1, however, GH-
CJDMM1 case 2 showed more severe SD in the frontal
cortex rather than occipital cortex and sparing of the en-
torhinal cortex and anterior basal ganglia, whereas both
cases (2 and 3) showed occasional laminar SD [26, 28].
A search of the literature yielded four GH-CJDMM
cases with extensive pathological assessment, which at
histopathological examination revealed either the pres-
ence (N = 3) [11, 12] or the absence (N = 1) [14, 32] of
kuru plaques, and general histopathological phenotypes
similar to those in our cases. Unfortunately, although the
presence of resPrPSc was confirmed by western blot in
three cases, typing of resPrPSc was not available in the
GH-CJDMM cases with kuru plaques [11], whereas
resPrPSc type 1 was demonstrated in GH-CJDMM lacking
kuru or other types of plaques (GH-CJDMM1) [14, 32]. A
positive PrP immunostaining was shown in the case report
of Delisle et al. [12]. All four cases presented with ataxia
but those with kuru plaques had ~ 6, 2.7 and 1.7 times
longer disease duration than the GH-CJDMM1 without
plaques (36, 16 and 10 months vs. 6 months). A longer
disease duration also was observed in our GH-CJDMM1
index case (14 months). The two phenotypes associated
with GH-CJDMM1 seem to share major pathological and
clinical features with those reported in the Japanese dCJD
cases. With the exception of two cases, all the Japanese
dCJD share the 129MM genotype [33]. The plaque-
associated cases (p-dCJD) are characterized clinically by
ataxia and slow disease progression and pathologically by
widespread PrP plaque deposition. The pathological
phenotype of p-dCJD would therefore share common
features with our index case with the exception of the
“stellate” PrP staining that, to our knowledge, has not been
reported in dCJD. Adding complexity to the plaque-
associated phenotype, however, is that different combina-
tions of PrP plaques (e.g., kuru, florid and eosinophilic)
were observed in both p-dCJD [34–36] and in GH-
CJDMM cases with plaques [11, 12]. The presence of
florid plaques and “stellate” cells deposition in both GH-
CJDMM1 and vCJD is intriguing. Florid plaques, the
pathological hallmark of variant CJD (vCJD), also have
been described in p-dCJD [20, 35, 37–40].
In contrast to the p-dCJD, the non-plaque-type dCJD
(np-dCJD) cases were less likely to present clinically with
ataxia and disease progression was rapid [7, 20]. In
addition, the histopathological phenotype of the np-dCJD
cases was indistinguishable from that of sCJDMM1; the
np-dCJD phenotype thus would not fully match that of our
GH-CJDMM1 without plaques. Also, as our dCJDMM1and sCJDMM1 are indistinguishable, our dCJDMM1 and
the Japanese np-dCJD would share the same histopatho-
logical phenotype.
A seemingly major discrepancy between our GH-
CJDMM1 and the Japanese dCJDMM1 patients is
represented by the size of the resPrPSc. The ~20 kDa
molecular size of the unglycosylated resPrPSc in our
three GH-CJDMM1 cases matched that of the ungly-
cosylated resPrPSc type 1 of sCJDMM1 (Fig. 4a-b)
[26]. In contrast, the unglycosylated resPrPSc in
Japanese dCJD migrated ~1 kDa faster in p-dCJD than
np-dCJD (e.g., ~20 kDa vs. ~21 kDa, respectively) [33].
Moreover, resPrPSc from np-dCJD and Japanese
sCJDMM1 was shown to co-migrate to ~21 kDa [33]
although divergent data also have been reported
[34, 35, 38, 40–42]. The ~1 kDa difference in gel mobil-
ity of resPrPSc type 1 of sCJDMM1 observed in our and
Kobayashi’s experiments [33] may reflect differences in
experimental conditions, such as the buffer pH and
buffer capacity [27, 28]. It has been shown that PK
digestion of PrPSc carried out at buffer pHs either < or >
than 7.2 has a major effect on the mobility of resPrPSc.
At pHs < 7.2, the unglyc. resPrPSc type 1 from
sCJDMM1 migrates to ~21 kDa whereas at pHs > 7.2
(our buffer pH is 8.0) resPrPSc type 1 migrates to
~20 kDa [26–28]. Thus, gel mobility of resPrPSc type 1
in sCJDMM1 is influenced by the pH.
It has been hypothesized that the phenotype with kuru
plaques in p-dCJD is caused by a cross-sequence trans-
mission of sCJDMV2 or sCJDVV2 prions to dura mater
recipients with 129MM genotype, whereas the lack of
kuru plaques in np-dCJD would be explained by an in-
fection with prions from sCJDMM1 [33, 43, 44]. Because
Japanese dCJD and our GH-CJDMM1 show similar
major divergent pathological phenotypes, it is conceiv-
able that a similar phenomenon occurred in GH-CJD,
with pools of growth hormone being contaminated with
different prion strains of sCJD. Of note, iCJD cases with
sCJDVV1- or sCJDMM2-like phenotypes have not been
reported, likely due to the rarity and poor transmissibil-
ity to humanized transgenic (Tg) mice of these two sCJD
subtypes [45].
There are also several unusual clinical features of our
index case that, to our knowledge, have not previously
been reported in GH-CJD. These include MRI evidence
of deep nuclei to cortical spread and his symptoms of
dysautonomia, dry cough, and sensorimotor neuropathy.
Interestingly, his dysautonomia began approximately
1.5 years prior to cerebellar symptoms. It is possible that
these symptoms occurred in prior cases, but might not
have been considered as part of the iCJD syndrome.
When treatments become available, knowing the pro-
dromal symptoms might allow earlier diagnosis and
intervention.
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The similarity of the two phenotypes we observed in
GH-CJDMM1 compared to the two phenotypes reported
in dCJDMM1 suggests that despite the difference of the
portal of entry and routes of propagation, the exogenous
PrPSc triggering the disease undergoes a similar process
of adaptation. Furthermore, it is possible that the ex-
ogenous PrPSc belonged to more than one strain of sCJD
or the strain adaptation resulted in a hybrid strain. A de-
tailed analysis of the molecular features in both groups
of GH-CJDMM1 and a transmission study to humanized
Tg mice would help to understand the molecular mecha-
nism(s) underlying the two pathological phenotypes.
Our study broadens the spectrum of possible patho-
logical phenotypes among the GH-CJDMM1 patients
and underscores the importance of a neuropathology
surveillance system in obtaining new information and
insights about the prion diseases.
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